[1] Bray F, Ferlay J, Soerjomataram I,et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. A Cancer J Clin,2018,68:394-424. [2] Petrovich Z,Jozsef G,Brady LW,et al.Radiotherapy for carcinoma of the bladder.A review[J]. Am J Clin Oncol,2001,24:1-9. [3] 范欣荣,李汉忠,纪志刚,等.保留器官的综合治疗—膀胱癌治疗的新模式(附107例报告)[J].中华泌尿外科杂志,2016,37:131-134. [4] 洪潮,陈小丹,张怀文,等.宫颈癌术后旋转调强放疗技术与固定野调强放疗技术的比较[J].实用癌症杂志,2015,30:1821-1825. [5] Ruchala KJ,Olivera GH,Kapatoes JM.Limited-data imageregistration for radiotherapy positioning and verification[J].Int J Radiat Oncol Biol Phys,2002,5:592-605. [6] Mackie TR,Holmes T,Swerdloff S,et al.Tomotherapy:a new concept for the delivery of dynamic conformal radiotherapy[J].Med Phys,1993,20:1709-1719. [7] Merseburger AS,Kuczyk MA. The value of bladder consercing strategies in muscle-invasicve bladder carcinoma compared with radical surgery[J].Curr Opin Urol, 2007,17:358-362. [8] Rodel C,Grabenbauer GG,Kuhn R,et al.Combined modality treatment and selective organ preservation in invasive bladder cancer:long-term results[J]. Clin Oncol,2002,20:3061-3071. [9] 张菡奕,路顺,郎锦义,等.宫颈癌放射治疗剂量对局部控制率与毒副反应的分析[J].实用医院临床杂志,2019,16:36-40. [10] Erridge SC,Seppenwoolde Y,Muller SH,et al.Portal imaging toassess set-up errors,tumor motion and tumor shrinkage duringconformal radiotherapy of non-small cell lung cancer[J].Radiother Oncol, 2003,66:75-85. [11] 周桂霞,戴相昆,徐寿平,等.乳腺癌术后放疗3种治疗计划的剂量学研究[J].中华放射医学与防护杂志,2010:314-316. [12] 崔迪,戴相昆,马林,等.鼻咽癌螺旋断层放疗与常规加速器调强放疗的剂量学比较[J].中华放射肿瘤学杂志,2008:169-173. [13] 戴相昆,蔡博宁,葛瑞刚,等.胸上段食管癌螺旋断层放疗和容积旋转调强放疗的剂量学比较[J].中华放射医学与防护杂志,2016,36:58-62. |